1. BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropenia
- Author
-
Jai Rautela, Peter E. Czabotar, Tobias Kratina, Christine R. Keenan, Yifan Zhan, Huon L. Wong, Nicholas D. Huntington, Manuela S Hancock, Christine A White, Emma M. Carrington, Ahmad Wardak, Vanessa L. Bryant, Wesley Wong, Rhys S. Allan, Guillaume Lessene, Yuyan Yang, Damian B D'Silva, Robyn L Schenk, Andrew M. Lew, Jacinta Hansen, Nadia Iannarella, Marco J Herold, Cynthia Louis, Robyn M. Sutherland, Ian P. Wicks, and Duong Nhu
- Subjects
0301 basic medicine ,Neutropenia ,Neutrophils ,Longevity ,Inflammation ,Bcl-xL ,Apoptosis ,Granulocyte ,03 medical and health sciences ,Phagocytes, Granulocytes, and Myelopoiesis ,Mice ,0302 clinical medicine ,medicine ,Animals ,biology ,business.industry ,Hematology ,Colony-stimulating factor ,medicine.disease ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Immunology ,biology.protein ,Bone marrow ,medicine.symptom ,business ,Ex vivo - Abstract
Neutrophils help to clear pathogens and cellular debris, but can also cause collateral damage within inflamed tissues. Prolonged neutrophil residency within an inflammatory niche can exacerbate tissue pathology. Using both genetic and pharmacological approaches, we show that BCL-XL is required for the persistence of neutrophils within inflammatory sites in mice. We demonstrate that a selective BCL-XL inhibitor (A-1331852) has therapeutic potential by causing apoptosis in inflammatory human neutrophils ex vivo. Moreover, in murine models of acute and chronic inflammatory disease, it reduced inflammatory neutrophil numbers and ameliorated tissue pathology. In contrast, there was minimal effect on circulating neutrophils. Thus, we show a differential survival requirement in activated neutrophils for BCL-XL and reveal a new therapeutic approach to neutrophil-mediated diseases.
- Published
- 2021